CNC

Centene CorporationNYSE · Managed Health Care · Health Care

Previous close

66.01

Change

−1.65 / −2.44%

FinDog View

Neutral

52-Week Range

31.63 – 69.63

P/E (TTM)

—

Forward P/E

13.6

Based on consensus earnings for the next 12 months

Market Cap

$32.6B

+2.48%

S&P 500 −2.41% over same period

Volume / Avg Volume

4.3M / 4.0M

1.06× average

Price History

Closing price · USD1M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q2 Quarter ended 2026-06	2026-07-28	$44.4B	2.51 / 1.10	−3.27%	Pending
FY2025 Q4 Quarter ended 2025-12	2026-02-06	—	— / —	−3.66%	Pending
FY2025 Q3 Quarter ended 2025-09	2025-10-29	—	— / —	−6.21%	Pending
FY2025 Q2 Quarter ended 2025-06	2025-07-01	—	— / —	−40.37%	Pending
FY2026 Q1 Quarter ended 2026-03	2025-04-25	$44.7B	3.37 / 2.15	−6.32%	Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

A 5-year P/E range needs a longer earnings record; not yet comparable

Last 4 quarters: $35.0M in buybacks + $0 in dividends, 0.11% of market cap combined

P/E (TTM)

—

P/B

1.5

P/S

0.2

PEG

—

Earnings Reaction

Over the last 5 reports, the stock moved ±12.0% on average on the first trading day after, rising 0 times

Most recent −3.27%

Volatility & Correlation

1-year beta 0.20 · Correlation with S&P 500 0.06Low beta

Annualized volatility 45% vs. 14% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 2 · $6.9MNet selling $6.9M

08-26KOSTER CHRISTOPHERSecretary & General CounselSell$3.8M56,500 shares · Avg price 66.90
08-18KOSTER CHRISTOPHERSecretary & General CounselSell$3.1M47,603 shares · Avg price 65.36

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q2	44.38	+4.5%	98.4%	1.20	1.09	3.42	2.19
FY2026 Q1	44.66	+5.1%	98.4%	1.86	1.54	4.17	3.11
FY2025 Q4	44.73	+23.2%	98.5%	-1.75	-1.10	0.22	-2.15
FY2025 Q3	44.90	+21.7%	98.6%	-6.95	-6.63	1.15	-13.50
FY2025 Q2	42.47	+18.1%	98.5%	-0.46	-0.25	1.58	-0.51
FY2025 Q1	42.49	+16.9%	98.4%	1.53	1.31	1.38	2.63
FY2024 Q4	36.30	+2.7%	98.1%	0.18	0.28	-0.74	0.63
FY2024 Q3	36.90	+5.5%	98.1%	0.67	0.71	-1.13	1.36
FY2024 Q2	35.97	+3.3%	98.1%	1.23	1.15	1.99	2.16
FY2024 Q1	36.34	+4.0%	98.2%	1.11	1.16	-0.61	2.16
FY2023 Q4	35.34	+5.3%	97.3%	-0.19	0.05	-0.01	0.12
FY2023 Q3	34.97	+3.7%	97.6%	0.74	0.47	0.89	0.87

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
CNC	Centene Corporation	$32.6B	—	+4.5%	98.4%	+2.48%	Neutral
LLY	Lilly (Eli)	$1.07T	39.9	+47.7%	85.8%	−3.83%	Bullish	Compare
JNJ	Johnson & Johnson	$644B	30.6	+6.6%	68.2%	+1.87%	Bullish	Compare
ABBV	AbbVie	$464B	73.7	+10.2%	74.7%	+4.87%	Neutral	Compare
MRK	Merck & Co.	$358B	112.2	+5.1%	73.5%	+6.57%	Neutral	Compare
UNH	UnitedHealth Group	$337B	23.9	+0.4%	88.1%	−5.15%	Neutral	Compare
TMO	Thermo Fisher Scientific	$240B	34.4	+10.5%	—	+10.75%	Bullish	Compare
AMGN	Amgen	$203B	23.3	+9.5%	72.0%	−10.26%	Neutral	Compare
GILD	Gilead Sciences	$183B	—	+10.2%	79.8%	+6.31%	Neutral	Compare

The View in One Line

No financial data; company reaffirmed FY2026 EPS guidance but lacks details; Neutral.

Updated 2026-09-16

Notable Institutional Holders

Renaissance Technologies$141MAdded +30%
Citadel Advisors · Ken Griffin$64.7MReduced −42%
Bridgewater Associates · Ray Dalio$24.9MAdded +130%

As of 2026-06-30

Key Events

08-17Management Change
Centene CFO to Retire at Year-End; Neczypor to Succeed
Centene CFO Andrew Asher will retire on December 31, 2026, and Christopher Neczypor will succeed him as CFO on January 1, 2027.Source ↗
07-29Capital Actions
Centene Partially Redeems $500 Million of 2027 Notes
Centene will redeem $500 million of its 4.25% notes at 100% of principal on August 13, 2026, leaving approximately $568.7 million outstanding after the redemption.Source ↗
07-28Management Change
Director Burdick Resigns; Paul Diaz Succeeds Him
Centene director Kenneth Burdick resigned on July 28, 2026, and the board elected Paul Diaz to succeed him, with a term through the 2027 annual meeting.Source ↗
06-22Management Change
Centene Board Grows to 10 with New Director
Effective June 19, 2026, Centene's board increased from 9 to 10 members, and Lauren Tyler was elected as a director, serving until the 2027 annual meeting.Source ↗
05-15Governance
Centene Annual Meeting Elects Directors and Confirms Executive Team
At the May 12, 2026 annual meeting, nine directors were elected, the executive compensation plan and KPMG's audit appointment were approved, and an independent chairman proposal was not passed.Source ↗
03-24Management Change
Centene Names New Chief Accounting Officer; Incumbent Moves to SVP of Finance Operations
Effective March 18, 2026, Theodore Pienkos becomes Centene's controller and chief accounting officer with a base salary of $440,000; former chief accounting officer Kate Casso moves to senior vice president of finance operations and innovation.Source ↗

Key Financial Trends

Quarterly Revenue ($B)44.4

Gross Margin98.4%

Free Cash Flow ($B)3.4